04 2025.11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
03 2025.11
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCT
30 2025.10
(1) RENEWAL OF CONTINUING CONNECTED TRANSACTIONS; AND (2) RENEWAL OF ONE-OFF CONNECTED TRANSACTIONS
17 2025.10
DATE OF BOARD MEETING
25 2025.09
2025 Interim Report
29 2025.08
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCT
27 2025.08
VOLUNTARY ANNOUNCEMENT - Telitacicept Meets Primary Endpoint in Stage A of Phase III Clinical Trial for the Treatment of IgA Nephropathy in China
22 2025.08
AMENDMENTS TO THE ARTICLES OF ASSOCIATION
22 2025.08
ARTICLES OF ASSOCIATION
22 2025.08
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
30 2025.10
2025 THIRD QUARTERLY REPORT
08 2025.10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
27 2025.03
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
04 2024.12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
05 2024.11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
29 2024.10
2024 THIRD QUARTERLY REPORT
07 2024.10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
25 2024.09
2024 Interim Report
05 2024.09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
16 2024.08
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
28 2024.06
ARTICLES OF ASSOCIATION
19 2022.04
Constitutional Documents ARTICLES OF ASSOCIATION
31 2022.03
Constitutional Documents - ARTICLES OF ASSOCIATION
06 2020.11
Constitutional Documents - ARTICLES OF ASSOCIATION
06 2020.11
SHAREHOLDERS’ COMMUNICATION POLICY
06 2020.11
PROCEDURES FOR SHAREHOLDERS TO NOMINATE AN INDIVIDUAL AS A DIRECTOR OR A SUPERVISOR OF THE COMPANY
06 2020.11
BOARD DIVERSITY POLICY